Font Size
Share this article

Print Friendly Version
04 March 2020

NMC Health founder considering selling pharma business

Neopharma could be valued at between $700 million and $1 billion and the pharmaceuticals business operates in about 50 countries in the Middle East, Africa and Asia

Bavaguthu Raghuram Shetty, the founder of NMC Health and Chairman of UAE Exchange

by Bloomberg

NMC Health founder Bavaguthu Raghuram Shetty is considering selling his Abu Dhabi-based pharmaceuticals business, Neopharma, after drawing interest from potential investors.

BR Shetty, who resigned as Chairman of the beleaguering hospital operator in February 2020, has been approached by parties including regional investors and family offices.

The Indian entrepreneur, who left over concerns that he may have misreported the size of his stake in NMC Health, may sell all or part of Neopharma and use the proceeds to repay loans.

BR Shetty is working with Houlihan Lokey to explore strategic options for BRS Ventures after NMC Health became entangled in allegations of fraud.

The NMC Health founder had been considering selling shares in Neopharma before a December 2019 report by short-seller Carson Block alleged that the hospital operator had overpaid for assets, inflated cash balances and understated debt.

Since then, NMC Health has lost two-thirds of its value and five of 11 board members have either been fired or resigned amid a series of financial improprieties.

Earlier this week, NMC Health asked lenders for a reprieve on its debt and Moody’s slashed its rating by five levels, saying its financial statements cannot be relied on.


RELATED STORIES: NMC Health Neopharma BR Shetty Carson Block





CPI Financial was established in Dubai in 1999 to meet the needs of an ever-expanding financial community, offering a comprehensive portfolio of market-leading products and services tailor-made for the banking and financial services sectors.

Subscribe to our News Letter


© 2019 CPI Financial. All rights reserved.

No part of this website may be reproduced or used in any form of advertising without prior permission in writing from the editor.